Yorikane R, Sada T, Koike H
Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
J Cardiovasc Pharmacol. 1992 Dec;20(6):955-60. doi: 10.1097/00005344-199212000-00016.
RS-2135 is the (+) isomer of a novel, fused carbazol derivative. The agent, when administered orally, shows long-lasting antiarrhythmic effects in several models of arrhythmia. We used standard microelectrode techniques to characterize the electrophysiological effects of the agent on canine Purkinje fibers. RS-2135 reduced the maximum upstroke velocity of the action potential (Vmax) and shortened the action potential duration (APD) in a concentration-related manner (0.3-3 microM). RS-2135 decreased Vmax at lower concentrations than disopyramide, flecainide, and mexiletine. RS-2135 shortened the effective refractory period (ERP), but significantly increased the ratio of ERP to APD90. Additionally, the effects of the (-) optical isomer of RS-2135 were compared with those of RS-2135, the (+) enantiomer. The (-) isomer was much less potent than RS-2135 in decreasing Vmax. These data suggest that RS-2135 belongs to the class I or "local anesthetic" type of antiarrhythmic agent and that the stereochemistry of the drug molecule is an important determinant of Na channel blocking activity.
RS - 2135是一种新型稠合咔唑衍生物的(+)异构体。该药物口服给药时,在多种心律失常模型中显示出持久的抗心律失常作用。我们使用标准微电极技术来表征该药物对犬浦肯野纤维的电生理效应。RS - 2135以浓度相关的方式(0.3 - 3 microM)降低动作电位的最大上升速度(Vmax)并缩短动作电位持续时间(APD)。RS - 2135在比丙吡胺、氟卡尼和美西律更低的浓度下降低Vmax。RS - 2135缩短有效不应期(ERP),但显著增加ERP与APD90的比值。此外,将RS - 2135的(-)光学异构体的效应与(+)对映体RS - 2135的效应进行了比较。(-)异构体在降低Vmax方面的效力远低于RS - 2135。这些数据表明RS - 2135属于I类或“局部麻醉”型抗心律失常药物,并且药物分子的立体化学是钠通道阻断活性的重要决定因素。